Treatment optimization for HIV/HCV co-infected patients

Area of Science:

• Virology
• Infectious Diseases
• Hepatology

Background:

• Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) co-infection is prevalent globally.
• HCV co-infection exacerbates morbidity and mortality in HIV-infected individuals due to shared transmission routes.
• Previous HCV treatments were limited by low cure rates, adverse effects, and drug interactions with HIV medications.

Purpose of the Study:

• To review the epidemiology and clinical impact of HIV/HCV co-infection.
• To discuss current treatment strategies for HCV in patients with HIV.
• To highlight the transformative effect of direct-acting antiviral (DAA) agents in managing HCV/HIV co-infection.

Main Methods:

• Literature review of epidemiological data on HIV/HCV co-infection.
• Analysis of clinical outcomes associated with HCV in HIV-positive individuals.
• Evaluation of direct-acting antiviral (DAA) efficacy and safety in co-infected patients.

Main Results:

• HCV co-infection significantly increases the risk of liver and non-liver related complications in HIV patients.
• Direct-acting antiviral (DAA) therapies have revolutionized HCV treatment, offering high cure rates and improved tolerability.
• DAAs present a paradigm shift in managing HCV in the context of HIV co-infection, reducing treatment burdens.

Conclusions:

• HCV treatment is a priority for HIV-co-infected individuals.
• Direct-acting antiviral (DAA) agents are highly effective and well-tolerated for treating HCV in HIV co-infected patients.
• The advent of DAAs offers a significant opportunity to reduce the global burden of HIV/HCV co-infection and improve patient outcomes.